Targeting CDK2 could boost immunotherapy response in patients with a wide range of cancers, according to Dana-Farber science
September 02, 2026
September 02, 2026
BOSTON, Massachusetts, Sept. 2 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Targeting CDK2 could boost immunotherapy response in patients with a wide range of cancers, according to Dana-Farber science
*
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a . . .
* * *
Targeting CDK2 could boost immunotherapy response in patients with a wide range of cancers, according to Dana-Farber science
*
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a . . .